{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040653","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.685594+00:00","generated_at":"2026-06-11T22:27:43.084751+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"4DMT reports Q2 net loss $29.6M; cash $310M; positive interim data for 4D-150 and 4D-710; Astellas deal","bullets":["Q2 net loss $29.6M ($28.1M prior year); R&D expense $23.6M; cash $310M as of June 30, 2023.","Cash includes $129M net public offering proceeds and $20M Astellas upfront; expected to fund into H1 2026.","Positive interim 4D-150 data: 100% reduction in anti-VEGF injections at high dose; durable response >1 year.","Phase 2 Dose Expansion of 4D-150 completed enrollment of 50 patients nearly two quarters ahead of schedule.","License with Astellas: $20M upfront, up to $942.5M milestones plus royalties for R100 vector in rare ophthalmic diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040653","json":"https://secwatch.observer/filing/0000950170-23-040653.json","markdown":"https://secwatch.observer/filing/0000950170-23-040653.md","text":"https://secwatch.observer/filing/0000950170-23-040653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017023040653/0000950170-23-040653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017023040653/fdmt-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:27:43.084751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b28f1ff8637b0998d92f310511aed954fa118fc","claim":"4D Molecular Therapeutics, Inc. reported financial results for three months ended June 30, 2023.","evidence_excerpt":"On August 9, 2023, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017023040653/0000950170-23-040653-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}